Global Opioids Market, by Drug Class (Agonist (Codeine, Fentanyl, Meperidine, Methadone, Morphine, Hydrocodone, Diphenoxylate, Hydromorphone, Methylphenidate, Oxycodone, Oxymorphone) and Antagonist (Buprenorphine, Naloxone, Naltrexone, Methylnaltrexone, Nalbuphine)), by Therapeutic Application (Pain Management, Cough Treatment, Diarrhea Treatment), and by Geography - Trends and Forecast till 2025

  • Published On : Nov 2017 |
  • Pages : 313 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Opioids – Reducing body pain but increasing pain for regulatory authorities

Opioids are narcotics that act on opioid receptors to produce morphine-like effects. Medically they are primarily used for pain management and treatment of diarrhea and cough. Agonist and antagonist are the two types of Opioid drugs. Codeine, Fentanyl, Meperidine, Methadone, Morphine, Hydrocodone, Diphenoxylate, Hydromorphone, Methylphenidate, Oxycodone, and Oxymorphone are classified as agonists. Buprenorphine, Naloxone, Naltrexone, Methylnaltrexone, and Nalbuphine are classified as antagonists. Opioids are rampantly overused worldwide, owing to easy availability and the situation is more critical in developed countries, such as the U.S. This has led to government or regulatory intervention in sale and prescription of opioids in various countries. The prescription pattern of the drug is closely monitored by government and regulatory bodies. Moreover, stringent guidelines are published for opioids prescription along with public awareness about adverse side effects of opioid such as dependence on the drug on regular use. Furthermore, government bodies have directed drug-stores to limit opioids delivery and participate in government activates in addressing the opioid crisis.

The incidence of opioid prescription has increased rapidly in last two decades worldwide. However, the rate of prescription is much high in the U.S, owing to high prevalence of chronic pain and other related conditions. Moreover, majority of these prescriptions in the U.S are for patients addicted to this drug. According to World Drug Report 2017, 29.5 million people suffered from drug overuse disorder worldwide, of which around 70% were registered in the U.S. The U.S recorded around 59,000 to 65,000 deaths due to drug overdose in 2016, of which around two-thirds were due to opioids overuse.

The global opioids market was valued at US$ 28,252.3 million in 2016 and is expected to witness a CAGR of 5.3% over the forecast period (2016 - 2024).

Figure 1. Global Opioids Market, by Region, 2016 (US$ Mn)

opioids market

Source: Coherent Market Insights Analysis (2017)

Increasing incidence of chronic pain is expected to drive the opioids market growth

Incidences of chronic pain is on the rise across the globe, with the rate being much higher in developed economies such as the U.S., UK, Germany, and Canada. According to a study published by BMJ (British Medical Journal), in 2013, around one-third to one-half of the population in UK suffered from some kind of chronic pain. The situation is not quite different in other developed economies such as the U.S. and Japan. According to a study published in NCBI, in 2015, prevalence of chronic pain is estimated to be as high as 20% (one in five) in Japan. The aging population is rapidly increasing in all in developed economies, which is thus expected to further increase incidences of chronic pain, in turn increasing consumption of opioid drugs.

Cannabis as potential alternative for pain relief

Cannabis has recently gained attention from a diverse range of people, including medical professionals, independent health advocacy groups, and government organizations. Cannabis is projected to emerge as a potential alternative therapy to opioids, as it controls nausea associated with intake of opioid drugs, as well as vomiting and dizziness that often accompany severe, prolonged pain. Moreover, risk of addiction associated with cannabis intake is much lower as compared to that of opioids. A poll conducted by the New England Journal of Medicine, in 2013, found that 75% (3 out of 4) clinicians in the U.S. recommended the use of cannabis for hypothetical cancer patients. Currently, medical marijuana is legal in 28 states and the District of Columbia, even though it is illegal under federal law. According to a research published, in 2017, in Annals of Internal Medicine, cannabis, which is also called medical marijuana, is used for pain management for 45-85% cases. However, the same research argues that there is little evidence to show that cannabis helps control chronic pain. Hence, an urgent need is experienced for high-quality clinical trials to test the clinical efficacy of marijuana in pain management. If clinical trials prove marijuana effective beyond a reasonable doubt, it is expected to emerge as a replacement for opioids.

Some of the major players operating in the global opioids market are Purdue Pharma, Titan Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Janssen Pharmaceuticals, Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Egalet Corporation, Endo Pharmaceuticals Inc., Allergan, Plc, and Pfizer Inc.

Opioid drugs bind to opioid receptors that are present in several areas of the nervous system such as the brain and spinal cord. Medically, they are primarily being used for pain relief. The drug class primarily used in relieving pain includes natural, semi-synthetic, and synthetic opioids. However, its application is not limited to pain relief alone and has been successfully used for treatment of various other medical conditions such as diarrhea and cough. Opioid drugs can be broadly divided into two categories, mild and major opioids, on the basis of its efficacy. Opioids can be administered as oral pills, parenteral, liquids, patches, or lozenges. Overdose and drug abuse is a major concern, with the situation alarming in developed regions. According to World Drug Report 2017, 29.5 million people suffered from drug use disorders in 2015 and staggering 70% of this 29.5 million were attributed to opioids only.

Market Dynamics

Incidence of chronic pain, which is primarily treated by opioids has witnessed continuous growth over the last decades. According to a report titled Pain in Europe, published in 2006, chronic pain affected around one in five (19%) adults, and prevalence was recorded to be the highest in Norway, Poland, and Italy, where one-fourth of adults were suffering from chronic pain. According to a study titled Prevalence of Chronic Pain in the UK, published in The BMJ (British Medical Journal), in 2013, chronic pain affects between one-third and one-half of the population in the U.K, indicating high prevalence rate. Prevalence rate is similar in other developed countries such as the U.S. Rapidly increasing incidence of chronic pain is thus expected to boost growth of the opioids market over the forecast period.

However, increasing usage of opioids, has led to increase in its overuse or abuse over the recent past. To tackle this situation, CDC published guidelines for prescribing opioids for chronic pain. Similar efforts to curtail opioid overuse are underway in developed economies of Europe. Such intervention by regulatory bodies are expected to obstruct growth of the opioids market.

Key Features of the Study:

  • This report provides in-depth analysis of the opioids market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2016 – 2024, considering 2014 & 2015 as the base years
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global opioids market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Purdue Pharma L.P., Titan Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Janssen Pharmaceuticals, Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Egalet Corporation, Endo Pharmaceuticals Inc., Allergan, Plc, and Pfizer Inc.
  • Insights from this report will allow marketers and the management authorities of companies to make informed decision with respect to their future product launch, technology upgrades, market expansion, and marketing tactics
  • The global opioids market report caters to various stakeholders in this industry, including investors, geriatric care service providers, assistive device manufacturers, distributors and suppliers, research and consulting firms, new entrants, and financial analysts
  • Various strategy matrices used in analyzing the opioids market would provide stakeholders vital inputs to make strategic decisions accordingly

Detailed Segmentation:

  • Global Opioids Market, By Drug Class:
    • Agonist
      • Codeine
      • Fentanyl
      • Meperidine
      • Methadone
      • Morphine
      • Hydrocodone
      • Diphenoxylate
      • Hydromorphone
      • Methylphenidate
      • Oxycodone
      • Oxymorphone
    • Antagonist
      • Buprenorphine
      • Naloxone
      • Naltrexone
      • Methylnaltrexone
      • Nalbuphine
  • Global Opioids Market, By Therapeutic Application:
    • Pain Management
      • Neuropathic Pain
      • Migraine
      • Back Pain
      • Osteoarthritis Pain
      • Cancer Pain
      • Others
    • Cough Treatment
    • Diarrhea Treatment
  • Global Opioids Market, By Geography:
    • North America
      • U.S.
        • By Drug Class
          • Agonist
            • Codeine
            • Fentanyl
            • Meperidine
            • Methadone
            • Morphine
            • Hydrocodone
            • Diphenoxylate
            • Hydromorphone
            • Methylphenidate
            • Oxycodone
            • Oxymorphone
          • Antagonist
            • Buprenorphine
            • Naloxone
            • Naltrexone
            • Methylnaltrexone
            • Nalbuphine
        • By Therapeutic Application
          • Pain Management
            • Neuropathic Pain
            • Migraine
            • Back Pain
            • Osteoarthritis Pain
            • Cancer Pain
            • Others
          • Cough Treatment
          • Diarrhea Treatment
      • Canada
        • By Drug Class
          • Agonist
            • Codeine
            • Fentanyl
            • Meperidine
            • Methadone
            • Morphine
            • Hydrocodone
            • Diphenoxylate
            • Hydromorphone
            • Methylphenidate
            • Oxycodone
            • Oxymorphone
          • Antagonist
            • Buprenorphine
            • Naloxone
            • Naltrexone
            • Methylnaltrexone
            • Nalbuphine
        • By Therapeutic Application
          • Pain Management
            • Neuropathic Pain
            • Migraine
            • Back Pain
            • Osteoarthritis Pain
            • Cancer Pain
            • Others
          • Cough Treatment
          • Diarrhea Treatment
    • Europe
      • U.K.
        • By Drug Class
          • Agonist
            • Codeine
            • Fentanyl
            • Meperidine
            • Methadone
            • Morphine
            • Hydrocodone
            • Diphenoxylate
            • Hydromorphone
            • Methylphenidate
            • Oxycodone
            • Oxymorphone
          • Antagonist
            • Buprenorphine
            • Naloxone
            • Naltrexone
            • Methylnaltrexone
            • Nalbuphine
        • By Therapeutic Application
          • Pain Management
            • Neuropathic Pain
            • Migraine
            • Back Pain
            • Osteoarthritis Pain
            • Cancer Pain
            • Others
          • Cough Treatment
          • Diarrhea Treatment
      • Germany
        • By Drug Class
          • Agonist
            • Codeine
            • Fentanyl
            • Meperidine
            • Methadone
            • Morphine
            • Hydrocodone
            • Diphenoxylate
            • Hydromorphone
            • Methylphenidate
            • Oxycodone
            • Oxymorphone
          • Antagonist
            • Buprenorphine
            • Naloxone
            • Naltrexone
            • Methylnaltrexone
            • Nalbuphine
        • By Therapeutic Application
          • Pain Management
            • Neuropathic Pain
            • Migraine
            • Back Pain
            • Osteoarthritis Pain
            • Cancer Pain
            • Others
          • Cough Treatment
          • Diarrhea Treatment
      • Italy
        • By Drug Class
          • Agonist
            • Codeine
            • Fentanyl
            • Meperidine
            • Methadone
            • Morphine
            • Hydrocodone
            • Diphenoxylate
            • Hydromorphone
            • Methylphenidate
            • Oxycodone
            • Oxymorphone
          • Antagonist
            • Buprenorphine
            • Naloxone
            • Naltrexone
            • Methylnaltrexone
            • Nalbuphine
        • By Therapeutic Application
          • Pain Management
            • Neuropathic Pain
            • Migraine
            • Back Pain
            • Osteoarthritis Pain
            • Cancer Pain
            • Others
          • Cough Treatment
          • Diarrhea Treatment
      • France
        • By Drug Class
          • Agonist
            • Codeine
            • Fentanyl
            • Meperidine
            • Methadone
            • Morphine
            • Hydrocodone
            • Diphenoxylate
            • Hydromorphone
            • Methylphenidate
            • Oxycodone
            • Oxymorphone
          • Antagonist
            • Buprenorphine
            • Naloxone
            • Naltrexone
            • Methylnaltrexone
            • Nalbuphine
        • By Therapeutic Application
          • Pain Management
            • Neuropathic Pain
            • Migraine
            • Back Pain
            • Osteoarthritis Pain
            • Cancer Pain
            • Others
          • Cough Treatment
          • Diarrhea Treatment
      • Spain
        • By Drug Class
          • Agonist
            • Codeine
            • Fentanyl
            • Meperidine
            • Methadone
            • Morphine
            • Hydrocodone
            • Diphenoxylate
            • Hydromorphone
            • Methylphenidate
            • Oxycodone
            • Oxymorphone
          • Antagonist
            • Buprenorphine
            • Naloxone
            • Naltrexone
            • Methylnaltrexone
            • Nalbuphine
        • By Therapeutic Application
          • Pain Management
            • Neuropathic Pain
            • Migraine
            • Back Pain
            • Osteoarthritis Pain
            • Cancer Pain
            • Others
          • Cough Treatment
          • Diarrhea Treatment
      • Russia
        • By Drug Class
          • Agonist
            • Codeine
            • Fentanyl
            • Meperidine
            • Methadone
            • Morphine
            • Hydrocodone
            • Diphenoxylate
            • Hydromorphone
            • Methylphenidate
            • Oxycodone
            • Oxymorphone
          • Antagonist
            • Buprenorphine
            • Naloxone
            • Naltrexone
            • Methylnaltrexone
            • Nalbuphine
        • By Therapeutic Application
          • Pain Management
            • Neuropathic Pain
            • Migraine
            • Back Pain
            • Osteoarthritis Pain
            • Cancer Pain
            • Others
          • Cough Treatment
          • Diarrhea Treatment
      • Rest of Europe
        • By Drug Class
          • Agonist
            • Codeine
            • Fentanyl
            • Meperidine
            • Methadone
            • Morphine
            • Hydrocodone
            • Diphenoxylate
            • Hydromorphone
            • Methylphenidate
            • Oxycodone
            • Oxymorphone
          • Antagonist
            • Buprenorphine
            • Naloxone
            • Naltrexone
            • Methylnaltrexone
            • Nalbuphine
        • By Therapeutic Application
          • Pain Management
            • Neuropathic Pain
            • Migraine
            • Back Pain
            • Osteoarthritis Pain
            • Cancer Pain
            • Others
          • Cough Treatment
          • Diarrhea Treatment
    • Asia-Pacific
      • China
        • By Drug Class
          • Agonist
            • Codeine
            • Fentanyl
            • Meperidine
            • Methadone
            • Morphine
            • Hydrocodone
            • Diphenoxylate
            • Hydromorphone
            • Methylphenidate
            • Oxycodone
            • Oxymorphone
          • Antagonist
            • Buprenorphine
            • Naloxone
            • Naltrexone
            • Methylnaltrexone
            • Nalbuphine
        • By Therapeutic Application
          • Pain Management
            • Neuropathic Pain
            • Migraine
            • Back Pain
            • Osteoarthritis Pain
            • Cancer Pain
            • Others
          • Cough Treatment
          • Diarrhea Treatment
      • India
        • By Drug Class
          • Agonist
            • Codeine
            • Fentanyl
            • Meperidine
            • Methadone
            • Morphine
            • Hydrocodone
            • Diphenoxylate
            • Hydromorphone
            • Methylphenidate
            • Oxycodone
            • Oxymorphone
          • Antagonist
            • Buprenorphine
            • Naloxone
            • Naltrexone
            • Methylnaltrexone
            • Nalbuphine
        • By Therapeutic Application
          • Pain Management
            • Neuropathic Pain
            • Migraine
            • Back Pain
            • Osteoarthritis Pain
            • Cancer Pain
            • Others
          • Cough Treatment
          • Diarrhea Treatment
      • Japan
        • By Drug Class
          • Agonist
            • Codeine
            • Fentanyl
            • Meperidine
            • Methadone
            • Morphine
            • Hydrocodone
            • Diphenoxylate
            • Hydromorphone
            • Methylphenidate
            • Oxycodone
            • Oxymorphone
          • Antagonist
            • Buprenorphine
            • Naloxone
            • Naltrexone
            • Methylnaltrexone
            • Nalbuphine
        • By Therapeutic Application
          • Pain Management
            • Neuropathic Pain
            • Migraine
            • Back Pain
            • Osteoarthritis Pain
            • Cancer Pain
            • Others
          • Cough Treatment
          • Diarrhea Treatment
      • ASEAN
        • By Drug Class
          • Agonist
            • Codeine
            • Fentanyl
            • Meperidine
            • Methadone
            • Morphine
            • Hydrocodone
            • Diphenoxylate
            • Hydromorphone
            • Methylphenidate
            • Oxycodone
            • Oxymorphone
          • Antagonist
            • Buprenorphine
            • Naloxone
            • Naltrexone
            • Methylnaltrexone
            • Nalbuphine
        • By Therapeutic Application
          • Pain Management
            • Neuropathic Pain
            • Migraine
            • Back Pain
            • Osteoarthritis Pain
            • Cancer Pain
            • Others
          • Cough Treatment
          • Diarrhea Treatment
      • Australia
        • By Drug Class
          • Agonist
            • Codeine
            • Fentanyl
            • Meperidine
            • Methadone
            • Morphine
            • Hydrocodone
            • Diphenoxylate
            • Hydromorphone
            • Methylphenidate
            • Oxycodone
            • Oxymorphone
          • Antagonist
            • Buprenorphine
            • Naloxone
            • Naltrexone
            • Methylnaltrexone
            • Nalbuphine
        • By Therapeutic Application
          • Pain Management
            • Neuropathic Pain
            • Migraine
            • Back Pain
            • Osteoarthritis Pain
            • Cancer Pain
            • Others
          • Cough Treatment
          • Diarrhea Treatment
      • South Korea
        • By Drug Class
          • Agonist
            • Codeine
            • Fentanyl
            • Meperidine
            • Methadone
            • Morphine
            • Hydrocodone
            • Diphenoxylate
            • Hydromorphone
            • Methylphenidate
            • Oxycodone
            • Oxymorphone
          • Antagonist
            • Buprenorphine
            • Naloxone
            • Naltrexone
            • Methylnaltrexone
            • Nalbuphine
        • By Therapeutic Application
          • Pain Management
            • Neuropathic Pain
            • Migraine
            • Back Pain
            • Osteoarthritis Pain
            • Cancer Pain
            • Others
          • Cough Treatment
          • Diarrhea Treatment
      • Rest of Asia Pacific
        • By Drug Class
          • Agonist
            • Codeine
            • Fentanyl
            • Meperidine
            • Methadone
            • Morphine
            • Hydrocodone
            • Diphenoxylate
            • Hydromorphone
            • Methylphenidate
            • Oxycodone
            • Oxymorphone
          • Antagonist
            • Buprenorphine
            • Naloxone
            • Naltrexone
            • Methylnaltrexone
            • Nalbuphine
        • By Therapeutic Application
          • Pain Management
            • Neuropathic Pain
            • Migraine
            • Back Pain
            • Osteoarthritis Pain
            • Cancer Pain
            • Others
          • Cough Treatment
          • Diarrhea Treatment
    • Latin America
      • Brazil
        • By Drug Class
          • Agonist
            • Codeine
            • Fentanyl
            • Meperidine
            • Methadone
            • Morphine
            • Hydrocodone
            • Diphenoxylate
            • Hydromorphone
            • Methylphenidate
            • Oxycodone
            • Oxymorphone
          • Antagonist
            • Buprenorphine
            • Naloxone
            • Naltrexone
            • Methylnaltrexone
            • Nalbuphine
        • By Therapeutic Application
          • Pain Management
            • Neuropathic Pain
            • Migraine
            • Back Pain
            • Osteoarthritis Pain
            • Cancer Pain
            • Others
          • Cough Treatment
          • Diarrhea Treatment
      • Mexico
        • By Drug Class
          • Agonist
            • Codeine
            • Fentanyl
            • Meperidine
            • Methadone
            • Morphine
            • Hydrocodone
            • Diphenoxylate
            • Hydromorphone
            • Methylphenidate
            • Oxycodone
            • Oxymorphone
          • Antagonist
            • Buprenorphine
            • Naloxone
            • Naltrexone
            • Methylnaltrexone
            • Nalbuphine
        • By Therapeutic Application
          • Pain Management
            • Neuropathic Pain
            • Migraine
            • Back Pain
            • Osteoarthritis Pain
            • Cancer Pain
            • Others
          • Cough Treatment
          • Diarrhea Treatment
      • Argentina
        • By Drug Class
          • Agonist
            • Codeine
            • Fentanyl
            • Meperidine
            • Methadone
            • Morphine
            • Hydrocodone
            • Diphenoxylate
            • Hydromorphone
            • Methylphenidate
            • Oxycodone
            • Oxymorphone
          • Antagonist
            • Buprenorphine
            • Naloxone
            • Naltrexone
            • Methylnaltrexone
            • Nalbuphine
        • By Therapeutic Application
          • Pain Management
            • Neuropathic Pain
            • Migraine
            • Back Pain
            • Osteoarthritis Pain
            • Cancer Pain
            • Others
          • Cough Treatment
          • Diarrhea Treatment
      • Rest of Latin America
        • By Drug Class
          • Agonist
            • Codeine
            • Fentanyl
            • Meperidine
            • Methadone
            • Morphine
            • Hydrocodone
            • Diphenoxylate
            • Hydromorphone
            • Methylphenidate
            • Oxycodone
            • Oxymorphone
          • Antagonist
            • Buprenorphine
            • Naloxone
            • Naltrexone
            • Methylnaltrexone
            • Nalbuphine
        • By Therapeutic Application
          • Pain Management
            • Neuropathic Pain
            • Migraine
            • Back Pain
            • Osteoarthritis Pain
            • Cancer Pain
            • Others
          • Cough Treatment
          • Diarrhea Treatment
    • Middle East
      • GCC
        • By Drug Class
          • Agonist
            • Codeine
            • Fentanyl
            • Meperidine
            • Methadone
            • Morphine
            • Hydrocodone
            • Diphenoxylate
            • Hydromorphone
            • Methylphenidate
            • Oxycodone
            • Oxymorphone
          • Antagonist
            • Buprenorphine
            • Naloxone
            • Naltrexone
            • Methylnaltrexone
            • Nalbuphine
        • By Therapeutic Application
          • Pain Management
            • Neuropathic Pain
            • Migraine
            • Back Pain
            • Osteoarthritis Pain
            • Cancer Pain
            • Others
          • Cough Treatment
          • Diarrhea Treatment
      • Israel
        • By Drug Class
          • Agonist
            • Codeine
            • Fentanyl
            • Meperidine
            • Methadone
            • Morphine
            • Hydrocodone
            • Diphenoxylate
            • Hydromorphone
            • Methylphenidate
            • Oxycodone
            • Oxymorphone
          • Antagonist
            • Buprenorphine
            • Naloxone
            • Naltrexone
            • Methylnaltrexone
            • Nalbuphine
        • By Therapeutic Application
          • Pain Management
            • Neuropathic Pain
            • Migraine
            • Back Pain
            • Osteoarthritis Pain
            • Cancer Pain
            • Others
          • Cough Treatment
          • Diarrhea Treatment
      • Rest of Middle East
        • By Drug Class
          • Agonist
            • Codeine
            • Fentanyl
            • Meperidine
            • Methadone
            • Morphine
            • Hydrocodone
            • Diphenoxylate
            • Hydromorphone
            • Methylphenidate
            • Oxycodone
            • Oxymorphone
          • Antagonist
            • Buprenorphine
            • Naloxone
            • Naltrexone
            • Methylnaltrexone
            • Nalbuphine
        • By Therapeutic Application
          • Pain Management
            • Neuropathic Pain
            • Migraine
            • Back Pain
            • Osteoarthritis Pain
            • Cancer Pain
            • Others
          • Cough Treatment
          • Diarrhea Treatment
    • Africa
      • North Africa
        • By Drug Class
          • Agonist
            • Codeine
            • Fentanyl
            • Meperidine
            • Methadone
            • Morphine
            • Hydrocodone
            • Diphenoxylate
            • Hydromorphone
            • Methylphenidate
            • Oxycodone
            • Oxymorphone
          • Antagonist
            • Buprenorphine
            • Naloxone
            • Naltrexone
            • Methylnaltrexone
            • Nalbuphine
        • By Therapeutic Application
          • Pain Management
            • Neuropathic Pain
            • Migraine
            • Back Pain
            • Osteoarthritis Pain
            • Cancer Pain
            • Others
          • Cough Treatment
          • Diarrhea Treatment
      • Central Africa
        • By Drug Class
          • Agonist
            • Codeine
            • Fentanyl
            • Meperidine
            • Methadone
            • Morphine
            • Hydrocodone
            • Diphenoxylate
            • Hydromorphone
            • Methylphenidate
            • Oxycodone
            • Oxymorphone
          • Antagonist
            • Buprenorphine
            • Naloxone
            • Naltrexone
            • Methylnaltrexone
            • Nalbuphine
        • By Therapeutic Application
          • Pain Management
            • Neuropathic Pain
            • Migraine
            • Back Pain
            • Osteoarthritis Pain
            • Cancer Pain
            • Others
          • Cough Treatment
          • Diarrhea Treatment
      • South Africa
        • By Drug Class
          • Agonist
            • Codeine
            • Fentanyl
            • Meperidine
            • Methadone
            • Morphine
            • Hydrocodone
            • Diphenoxylate
            • Hydromorphone
            • Methylphenidate
            • Oxycodone
            • Oxymorphone
          • Antagonist
            • Buprenorphine
            • Naloxone
            • Naltrexone
            • Methylnaltrexone
            • Nalbuphine
        • By Therapeutic Application
          • Pain Management
            • Neuropathic Pain
            • Migraine
            • Back Pain
            • Osteoarthritis Pain
            • Cancer Pain
            • Others
          • Cough Treatment
          • Diarrhea Treatment
  • Company Profiles
    • Purdue Pharma*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Titan pharmaceuticals
    • Boehringer Ingelheim
    • Janssen Pharmaceuticals, Inc.
    • Sanofi
    • Sun Pharmaceuticals
    • Mallinckrodt Pharmaceuticals
    • Egalet Corporation
    • Endo Pharmaceuticals Inc.
    • Allergan, Plc
    • Pfizer Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Therapeutic Application
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Regulatory Scenario
    • Reimbursement Scenario
    • Pricing Analysis
    • New Product Launches
    • Government Policies and Initiatives
  4. Global Opioids Market, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
    • Introduction
      • Market Share Analysis, 2015 and 2024 (%)
      • Y-o-Y Growth Analysis, 2014 - 2024
      • Segment Trends
    • Agonist
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
        • Codeine
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
        • Fentanyl
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
        • Meperidine
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
        • Methadone
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
        • Morphine
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
        • Hydrocodone
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
        • Diphenoxylate
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
        • Hydromorphone
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
        • Methylphenidate
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
        • Oxycodone
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
        • Oxymorphone
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
    • Antagonist
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
        • Buprenorphine
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
        • Naloxone
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
        • Naltrexone
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
        • Methylnaltrexone
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
        • Nalbuphine
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million & No. of Units)
  5. Global Opioids Market, By Therapeutic Application, 2014 - 2024 (US$ Million & No. of Units)
    • Introduction
      • Market Share Analysis, 2015 and 2024 (%)
      • Y-o-Y Growth Analysis, 2014 - 2024
      • Segment Trends
    • Pain Management
      • Introduction
      • Market Share Analysis, 2015 and 2024 (%)
      • Y-o-Y Growth Analysis, 2014 – 2024
        • Neuropathic Pain
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million)
        • Migraine
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million)
        • Back Pain
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million)
        • Osteoarthritis Pain
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million)
        • Cancer Pain
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million)
        • Others
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million)
    • Cough Treatment
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million)
    • Diarrhea Treatment
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2014 - 2024, (US$ Million)
  6. Global Opioids Market, By Regions, 2014 - 2024 (US$ Million & No. of Units)
    • Introduction
      • Market Share Analysis, By Region, 2015 and 2024 (%)
      • Y-o-Y Growth Analysis, For Regions, 2014 - 2024
    • North America
      • Market Share Analysis, By Country, 2015 and 2024 (%)
      • Y-o-Y Growth Analysis, By Country, 2014 - 2024
        • U.S.
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units & No. of Units)
          • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
        • Canada
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
          • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
    • Europe
      • Market Share Analysis, By Country, 2015 and 2024 (%)
      • Y-o-Y Growth Analysis, By Country, 2014 - 2024
        • U.K.
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
          • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
        • Germany
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
          • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
        • Italy
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
          • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
        • France
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
          • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
        • Russia
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
          • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
        • Rest of Europe
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
          • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
    • Asia Pacific
      • Market Share Analysis, By Country, 2015 and 2024 (%)
      • Y-o-Y Growth Analysis, By Country, 2014 - 2024
        • China
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
          • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
        • India
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
          • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
        • Japan
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
          • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
        • ASEAN
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
          • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
        • Australia
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
          • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
        • South Korea
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
          • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
        • Rest of Asia Pacific
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
          • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
    • Latin America
      • Market Share Analysis, By Country, 2015 and 2024 (%)
      • Y-o-Y Growth Analysis, By Country, 2014 - 2024
        • Brazil
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
          • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
        • Mexico
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
          • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
        • Rest of Latin America
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
          • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
    • Africa
      • Market Share Analysis, By Country, 2015 and 2024 (%)
      • Y-o-Y Growth Analysis, By Country, 2014 - 2024
        • Northern Africa
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
          • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
        • Central Africa
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
          • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
        • South Africa
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
          • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
    • Middle East
      • Market Share Analysis, By Country, 2015 and 2024 (%)
      • Y-o-Y Growth Analysis, By Country, 2014 - 2024
        • GCC Countries
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
          • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
        • Israel
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
          • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
        • Rest of Middle East
          • Country Trends
          • Market Size and Forecast, By Drug Class, 2014 - 2024 (US$ Million & No. of Units)
          • Market Size and Forecast, By Therapeutic Application, 2014 - 2024 (US$ Million)
  7. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis (3x3 Matrix)
    • Company Profiles
      • Purdue Pharma
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Titan Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Boehringer Ingelheim
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Janssen Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Sanofi
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Mallinckrodt Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Egalet Corporation
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Endo Pharmaceuticals Inc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Allergan Plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Sun Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
    • Analyst Views
  8. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 130 market data tables and 42 figures on "Opioids Market - Global forecast to 2024”.

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.